GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings Inc. (NYSE-MKT: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced the company plans to participate in the 37th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA.
Senseonics’ management is scheduled to present on Thursday, August 10, 2017 at 1:00pm ET. Interested parties may access a webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ first generation continuous glucose monitoring (CGM) system, Eversense®, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels. For more information on Senseonics, please visit www.senseonics.com.